Luoxin Pharmaceuticals Group Stock Co Ltd Net Asset Quality Index
Luoxin Pharmaceuticals Group Stock Co Ltd net asset quality index. Luoxin Pharmaceuticals Group Stock Co Ltd (002793) has a Net Asset Quality Index of 33.3% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.61 Billion minus total liabilities of CN¥2.41 Billion yields net assets of CN¥1.20 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See net assets of Luoxin Pharmaceuticals Group Stock Co Lt for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Luoxin Pharmaceuticals Group Stock Co Ltd (2011–2025)
Net asset quality index of Luoxin Pharmaceuticals Group Stock Co Ltd from 2011 to 2025. This chart shows how Luoxin Pharmaceuticals Group Stock Co Ltd's Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the index stands at 33.3%, representing net assets of CN¥1.20 Billion against total assets of CN¥3.61 Billion CNY. Check 002793 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Luoxin Pharmaceuticals Group Stock Co Ltd Net Asset Quality Index by Year (2011–2025)
Luoxin Pharmaceuticals Group Stock Co Ltd net asset quality index by year from 2011 to 2025. The table below presents the year-by-year Net Asset Quality Index for Luoxin Pharmaceuticals Group Stock Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 002793 market cap.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 33.2% | CN¥1.24 Billion | CN¥3.73 Billion | CN¥2.49 Billion | ▼ -0.5 pp |
| 2024 | 33.7% | CN¥1.46 Billion | CN¥4.34 Billion | CN¥2.88 Billion | ▼ -16.6 pp |
| 2023 | 50.3% | CN¥2.57 Billion | CN¥5.12 Billion | CN¥2.54 Billion | ▲ +9.5 pp |
| 2022 | 40.8% | CN¥3.31 Billion | CN¥8.11 Billion | CN¥4.80 Billion | ▼ -9.1 pp |
| 2021 | 49.9% | CN¥4.74 Billion | CN¥9.50 Billion | CN¥4.76 Billion | ▼ -6.5 pp |
| 2020 | 56.3% | CN¥4.35 Billion | CN¥7.72 Billion | CN¥3.37 Billion | ▲ +3.2 pp |
| 2019 | 53.1% | CN¥3.96 Billion | CN¥7.46 Billion | CN¥3.50 Billion | ▼ -11.8 pp |
| 2018 | 64.9% | CN¥909.89 Million | CN¥1.40 Billion | CN¥491.85 Million | ▼ -19.0 pp |
| 2017 | 83.9% | CN¥754.19 Million | CN¥898.93 Million | CN¥144.74 Million | ▼ -2.0 pp |
| 2016 | 85.9% | CN¥698.33 Million | CN¥812.89 Million | CN¥114.56 Million | ▲ +24.1 pp |
| 2015 | 61.8% | CN¥339.50 Million | CN¥549.60 Million | CN¥210.10 Million | ▼ -8.7 pp |
| 2014 | 70.4% | CN¥315.46 Million | CN¥447.86 Million | CN¥132.40 Million | ▲ +1.2 pp |
| 2013 | 69.2% | CN¥251.50 Million | CN¥363.30 Million | CN¥111.80 Million | ▲ +14.0 pp |
| 2012 | 55.2% | CN¥205.54 Million | CN¥372.31 Million | CN¥166.77 Million | ▼ -0.6 pp |
| 2011 | 55.8% | CN¥151.87 Million | CN¥271.94 Million | CN¥120.07 Million | — |